Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label study where each patient will receive TOCOSOL(R) Paclitaxel 120mg/m2 every week for first line treatment of metastatic breast cancer. Patients will be followed to determine the efficacy of treatment (as measured by objective response rate), and the safety associated with weekly administration of TOCOSOL Paclitaxel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

NCT01221870

Breast Neoplasm

UNKNOWN PHASE2

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

NCT06835400

Metastatic Breast Cancer

NOT_YET_RECRUITING PHASE3

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

NCT00072852

Breast Neoplasms

COMPLETED PHASE2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

NCT00288249

Breast Neoplasms Breast Cancer, Metastatic

COMPLETED PHASE2

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

NCT00025688

Breast Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, non-randomized Phase 2 study of weekly administration of TOCOSOL Paclitaxel at a dose level, 120mg/m2, known to be tolerated based on Phase 2a studies of this investigational agent in patients with other histological diagnoses. This study is a fixed sample size design with no planned early stopping decision. The goals of the study include the determination of the safety of TOCOSOL Paclitaxel, and the objective response rate, defined by RECIST criteria as complete responses plus partial responses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TOCOSOL Paclitaxel

TOCOSOL Paclitaxel administered weekly at 120mg/mm2

Group Type EXPERIMENTAL

TOCOSOL(R) Paclitaxel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TOCOSOL(R) Paclitaxel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patient with histologic diagnosis of breast carcinoma
* Stage IV (M1) disease
* No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer
* Adult (18 years of age or older) patients
* Adequate hematologic function (ANC \>=1500 cells/mm3 and platelets \>100,000/mm3
* Serum creatinine \<=2.0 mg/dL
* Total bilirubin \<=1.5 mg/dL
* AST/SGOT and ALT/SGPT \<=3 times the upper limit of institutional normal values
* PT and PTT within institutional normal range
* ECOG performance status of 0-2
* At least one unidimensionally measurable lesion as defined by RECIST criteria assessable by radiographic evaluation
* A signed IRB/Ethics Committee approved Informed Consent
* Life expectancy of at least 12 weeks
* Fully recovered from any previous surgery
* A negative pregnancy test prior to study entry if premenopausal
* Agree not to take Vitamin E supplementation while receiving study medication

Exclusion Criteria

* Any prior taxane-containing chemotherapy including Taxol or Taxotere
* Patients who are pregnant or lactating
* Peripheral neuropathy NCI-CTC grade 2 or greater
* Wide-field radiation, hormonal therapy or trastuzumab within 4 weeks of first dose of study drug; cytotoxic chemotherapy within 6 months of first dose of study drug
* Treatment with an investigational agent within 4 weeks of first dose of study drug
* Patients with a history of carcinomas of primary sites which can not be distinguished histologically from metastatic breast carcinoma
* Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of metastatic breast carcinoma
* Brain metastases
* Active bowel obstruction
* Active, serious infection or other serious medical problems (other than metastatic breast cancer) likely to impair completion of the study protocol
* Concurrent therapy with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 or CYP3A4
* Concurrent therapy with warfarin or other coumarin derivatives

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No